Company / Free Cash Flow
ImmunityBio, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$308.8M
FY2025
5-year range
-$415.7M / -$156.4M
FY2021-FY2025
Trend
+22.4%
vs FY2024
Sector context
#170 of 194
Health Care
What the data says
ImmunityBio, Inc.'s free cash flow of -$309M is lower than 88% of companies in the Health Care sector (FY2025). Free Cash Flow has fluctuated over the past 10 years, ranging from -$416M in FY2022 to -$6M in FY2016.
Based on SEC 10-K filings.
-$309M in FY2025.
Improved from -$397M to -$309M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 194This company -$308.8M Sector average $470.8M
▼
-165.6% below sector average
Key checks
Key Insights
- In FY2025, free cash flow increased 22.4% year-over-year.
- Ranks #170 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2016.
- Lowest free cash flow in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -7.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$308.8M | +22.4% |
| FY2024 | -$398.1M | -0.2% |
| FY2023 | -$397.3M | +4.4% |
| FY2022 | -$415.7M | -165.8% |
| FY2021 | -$156.4M | +9.8% |
| FY2020 | -$173.4M | -10.9% |
| FY2019 | -$156.4M | -246.4% |
| FY2018 | -$45.2M | -63.9% |
| FY2017 | -$27.5M | -387.3% |
| FY2016 | -$5.7M | +79.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026